📇 Rhumatologue · ARGENTEUIL · (95) · Salarié

MME LEILA BOULOS-MANDELLI

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
82.6 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 ARGENTEUIL (95)SalariéRPPS 10001458933

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

IMAGERIE MEDICALE RIVES DE SEINE
40 T AV DU MARECHAL FOCH, 95100 ARGENTEUIL
Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Efficacy and Safety of Alirocumab and Evolocumab as Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis

Current medicinal chemistry · 2024

📚 13 citations🎯 RCR 2.33Top 22% NIH

Lire l'abstract Crossref ↓

Background: Familial hypercholesterolemia (FH) is a prevalent and potentially fatal illness that causes a substantial elevation in low-density lipoprotein cholesterol (LDL-C). Methods: A comprehensive search was done on PubMed/MEDLINE, EMBASE, Web of Science (WOS/ ISI), Scopus, ClinicalTrials (www.ClinicalTrials.gov), and conferences/ congress research papers. Random effect models were used to calculate mean differences (%) and risk ratios (RRs), and confidence intervals (95%). Results: Ten studies (n=1489 patients) were included in this study. PCSK9 inhibitors decreased the levels of LDL-C by -49.59% (95%CI -55.5%, -43.67%) as compared to placebo. They also didn’t alter the Treatment-Emergent Adverse Event (TEAE) and neuronal events by RR 0.92 (0.75, 1.13) and 1.31 (0.66, 2.59), respectively. PCSK9 inhibitors were effective and safe in treating patients with FH. Conclusion: There was high-quality evidence showing that monoclonal antibodies (alirocumab & evolocumab) lower LDL-C (GRADE: high), lipoprotein (a) (GRADE: High), triglycerides (TG) (GRADE: High), total cholesterol (GRADE: High), non-high-density lipoprotein cholesterol (non- HDL-C) (GRADE: Moderate), and apolipoprotein B (GRADE: High), and increase the HDL-C (GRADE: High) as well as apolipoprotein A1 (GRADE: High). Comparing PCSK9 inhibitors against placebo, neither TEAE (GRADE: high) nor neuronal events (GRADE: moderate) were changed. Registration number: PROSPERO-CRD42022334035

Plastic pollution in the deep-sea Giant red shrimp, Aristaeomorpha foliacea, in the Eastern Ionian Sea; an alarm point on stock and human health safety

The Science of the total environment · 2023

📚 6 citations🎯 RCR 1.31

Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM

Neurological research · 2023

📚 5 citations

Cookies & analyse de trafic

MME LEILA BOULOS-MANDELLI

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal30

Case report / série6

Pédiatrie3

Épidémiologie & registres2

Pharmacovigilance2

Revue / méta-analyse2

Revue générale2

Biothérapies non-anti-TNF1

csDMARDs1

Économie santé1

IA en rhumatologie1

Microbiote1

Qualité de vie / PROMs1

Partager cette fiche